 ERG rearrangements (most commonly transmembrane protease, serine 2 [TMPRSS2]:ERG [T2:ERG] gene fusions) have been identified in approximately 50% of prostate cancers .     ///    Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden.. 